Navigation Links
Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Apr 13, 2007 - Ascenta Therapeutics, Inc. announced today that its small molecule portfolio of apoptosis-triggering compounds will be featured in three oral presentations and several poster presentations at next week's 2007 Annual Meeting of the American Association for Cancer Research (AACR), to be held in Los Angeles, California April 14-18, 2007.

Ascenta's MDM2 program has been selected for presentation at the "High Impact Late-Breaking Research 1" session on Tuesday, April 17 (Hall A at 3:30pm) and will be presented by Dajun Yang, MD, PhD, Senior Vice President of Research at Ascenta Therapeutics and General Manager of Ascenta's R&D Subsidiary in Shanghai, China. The MDM2 program will also be featured in a talk on Saturday, April 14 (Petree D at 4:15pm) by University of Michigan's Professor Shaomeng Wang, PhD, a co-founder of Ascenta.

Preclinical studies of AT-101, Ascenta's clinical stage, oral pan-Bcl-2 inhibitor, will be featured in an oral presentation by Dr. Yang on Wednesday, April 18 and in several poster presentations authored by Ascenta personnel and collaborating investigators. In a collaboration with scientists at Human Genome Sciences, Inc., studies of HGSI's TRAIL receptor agonist monoclonal antibodies in combination with Ascenta's small molecule XIAP inhibitors, will be presented in a poster session on Tuesday, April 17 (1pm-5pm). The full schedule of presentations featuring Ascenta's technology is as follows: -0-

Date      Time      Title                              Presenter,

                                                        Collaborator

--------- --------- ---------------------------------- --------------

Saturday  4:15pm    Potent, specific, non-peptidic     Shaomeng Wang,

April 14             small molecule inhibitors of the   PhD, U.

                     Human MDM2-p53 interaction as a    Michigan

                     new class of anticancer therapy

--------- --------- --------
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:4/21/2015)... OAKS, Calif., April 21, 2015 Amgen (NASDAQ: ... first quarter of 2015. Key results include: , ... of 2014 to $5,033 million, with 12 percent product ... Prolia ® (denosumab), EPOGEN ® (epoetin alfa), ... Unfavorable changes in foreign exchange rates impacted total revenue ...
(Date:4/21/2015)... , 21. April 2015  CorTechs Labs, ... quantitative Analyse des Hirnvolumens freut sich, eine ... Pharmaunternehmen, bekannt geben zu können. Die Unternehmen ... des Hirnvolumens zusammenarbeiten, der die Identifizierung, Messung ... Patienten mit multipler Sklerose als Ziel hat. ...
(Date:4/21/2015)... -- Lincoln Computer Services has taken a proactive approach to ... LCS donated 10 laptops and carts to the Good ... Home at Riverdale by RiverSpring ... is a creative, non-pharmacological approach to Alzheimer,s care that ... in the morning, start their day off in a ...
Breaking Medicine Technology:Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 2Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 3Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 4Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 5Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 6Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 7Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 8Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 9Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 10Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 11Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 12Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 13Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 14Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 15Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 16Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 17Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 18Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 19CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an 2Lincoln Continues Support of the Community: Donates 10 Laptops for Alzheimer's Program 2
... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will present updated results from its,Phase 2 ... a,poster discussion session at the International Association for ... on Lung Cancer in Seoul, Korea.,Details follow: ...
... - Positive Phase 2 Clinical Trial Results from PI-88 in ... $92.4 million in Raised Capital Highlight the Year ... PGL; Nasdaq: PGLA) today released its,financial results for the fiscal ... * Announced positive results from a Phase 2, 172 ...
Cached Medicine Technology:Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 2Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 3Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 2Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 3
(Date:4/21/2015)... WA (PRWEB) April 21, 2015 ... Practice Edition 2 for otolaryngologists, bringing the most ... the healthcare community. Otolaryngologists can now experience ... by a trusted source in the industry, Lyft, ... integration with leading EHRs. , “Lyft is very ...
(Date:4/21/2015)... 2015 QuickMedical, a veteran-owned leader ... now represents Schiller America's line of ... Tests, and Vital Signs Monitors, among many other ... a global leader in the development and production ... in close cooperation with the world's leading physicians ...
(Date:4/21/2015)... April 21, 2015 On April 8th, ... EcoLuxe Lounge at the world famous Avalon Hollywood. Organized ... product placement in TV and film, the EcoLuxe Lounge ... at many awards ceremonies and festivals throughout the year. ... of eco-friendly and socially conscious products and services, this ...
(Date:4/21/2015)... The 2015 Market Research Report on ... and in-depth study on the current state of ... a focus on the Chinese situation. , ... research are Cargill, Fbc Industries, Posy Pharmachem, Fuso, ... Lianyungang Mupro Fi, Yixing-Union, Debang Fine Chemical, Shuren ...
(Date:4/21/2015)... This year, in recognition of IAM, the Foundation ... publish a unique awareness campaign featuring real-life patients, affected ... of May and carry the message, "Be Inspired. Use ... was chosen to encourage the general public to learn ... support our mission of educating, inspiring and connecting all ...
Breaking Medicine News(10 mins):Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2
... LLC announces the pending release of its newest report, ... As a result of the March 9, 2009 reversal ... stem cell research, suppliers of stem cell related products are ... in the stem cell products market. In this report, BioInformatics, ...
... State University, discusses new research exploring weight discrimination against women in the workplace. , ... more information. , , , ... , , , , ... , , , , ...
... April 7 Did you know that April 16th is National Stress ... due? I don,t know, but spas can help. ISPA,s research shows ... relax and relieve or reduce stress. Here are some other facts ... 1/3 of Americans are living with extreme stress and nearly half ...
... Struggling with infertility issues on top of dealing with ... The troubled economy has slowed down, but biological clocks ... and men have biological clock realities. So, for ... they need some physical and financial help, there,s a ...
... Economic ActivitySACRAMENTO, Calif., April 7 California health plans ... economy, generating 130,000 jobs and $13.5 billion in economic ... by the California Association of Health Plans ... an outside consulting firm with expertise in health care ...
... Physicians for Human Rights responds to the publication of a ... that health professionals who participated in interrogations in CIA secret detention ... participated in torture. , ... Cambridge, MA (Vocus) April ...
Cached Medicine News:Health News:BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products 2Health News:BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products 3Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 2Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 3Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 4Health News:Spas Add Years to Your Life 2Health News:Infertility Issues and No Insurance Do Not Necessarily Mean No Hope for Baby 2Health News:California Health Plans Vital to State's Economy 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 3
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
... Digisonics has set the standard in ... review station, the only fully integrated ... multi-modality reporting., ,DigiView cardiology solutions bring ... professional reporting choices, an integrated clinical ...
... The menu-driven Vapro osmometer determines osmolality ... natural equilibrium. ,What you don't get are ... particles, or other conditions that interfere with ... percent in the clinical range) Vapro osmometer ...
Medicine Products: